Overview |
bs-9930R-BF350 |
KCNE2 Polyclonal Antibody, AbBy Fluor® 350 Conjugated |
WB, IF(IHC-P) |
Human, Mouse, Rat |
Specifications |
AbBy Fluor® 350 |
Rabbit |
KLH conjugated synthetic peptide derived from human KCNE2 |
51-123/123 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
Target |
9992 |
ATFB4; cardiac voltage gated potassium channel accessory subunit 2; Kcne2; KCNE2_HUMAN; LQT5; LQT6; minimum potassium ion channel related peptide 1; Minimum potassium ion channel-related peptide 1 antibody minK related peptide 1; MinK-related peptide 1; MIRP1; Potassium channel subunit beta MiRP1; potassium channel subunit, MiRP1; potassium voltage gated channel subfamily E member 2; potassium voltage gated channel, Isk related family, member 2; Potassium voltage-gated channel subfamily E member 2; voltage-gated K+ channel subunit MIRP1. |
Ancillary protein that assembles as a beta subunit with a voltage-gated potassium channel complex of pore-forming alpha subunits. Modulates the gating kinetics and enhances stability of the channel complex. Associated with KCNH2/HERG is proposed to form the rapidly activating component of the delayed rectifying potassium current in heart (IKr). May associate with KCNQ2 and/or KCNQ3 and modulate the native M-type current. May associate with KCNQ1/KVLTQ1 and elicit a voltage-independent current. May associate with HCN1 and HCN2 and increase potassium current. |
Application Dilution |
WB |
1:300-5000 |
IF(IHC-P) |
1:50-200 |